

Docket No. 245603US25CONT



15m

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Eva ALTMANN, et al.

SERIAL NO: 10/694,672

FILED: October 28, 2003

FOR: DIPEPTIDE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Charles L. Gholz

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

James J. Kelly, Ph.D.

Registration No. 41,504

MAR 16 2005

SHEET 1 OF 1

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

SERIAL NO.

245603US25CONT

10/694,672

## LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Eva ALTMANN, et al.

FILING DATE

October 28, 2003

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	2003/0096796	05/22/03	BRYANT ET AL			
	AB	2002/0086996	07/04/02	BRYANT ET AL			
	AC	2003/0119788	07/26/03	BRYANT ET AL			
	AD	2004/0147745	07/29/04	BRYANT ET AL			
	AE	6,476,026	11/05/02	BRYANT ET AL			
	AF	6,593,327	07/15/03	BRYANT ET AL			
	AG	6,455,502	09/24/02	BRYANT ET AL			
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO					
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AW	J. ROBICHAUD, et al., Biorganic & Medicinal Chemistry Letters, 14(2004), pp. 4291-4295, "Rational Design of Potent and Selective NH-linked Aryl/Heteroaryl Cathepsin K Inhibitors".
	AX	C. CHEN, et al., J. Org. Chem., 2003, 68, pp. 2633-2638, "Practical Asymmetric Synthesis of a Potent Cathepsin K Inhibitor. Efficient Palladium Removal Following Suzuki Coupling".
	AY	J. ROBICHAUD, et al., J. Med. Chem., 2003, 45, pp. 3709-3727, "A Novel Class of Nonpeptidic Biaryl Inhibitors of Human Cathepsin K".
	AZ	

☐ Additional References sheet(s) attached

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.